Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Costantinides, Fulvia; Rizzo, Roberto; Pascazio, Lorenzo; Maglione, Michele
• Is Part Of: BMC oral health. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 9
• Publication Date: 2016-12
• Subjects: Novel oral anticoagulants -- Dabigatran -- Rivaroxaban -- Apixaban -- Dental treatment; Oral medicine -- Periodicals; 617.522005
• DOI: 10.1186/s12903-016-0170-7
• Languages: English
• ISSNs: 1472-6831

Abstract

Abstract Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors), before, during and after dental treatment in light of the more recent knowledges. Discussion In dentistry and oral surgery, the major concerns in treatment of patients taking direct thrombin inhibitors and factor Xa inhibitors is the risk of haemorrhage and the absence of a specific reversal agent. The degree of renal function, the complexity of the surgical procedure and the patient's risk of bleeding due to other concomitant causes, are the most important factors to consider during surgical dental treatment of patients taking NOAs. For patients requiring simple dental extraction or minor oral surgery procedures, interruption of NOA is not generally necessary, while an higher control of bleeding and discontinuation of the drug (at least 24 h) should be requested before invasive surgical procedures, depending on renal functionality. Summary The clinician has to consider that the number of patients taking NOAs is rapidly increasing. Since available data are not sufficient to establish an evidence-based dental management, the dentist must use caution and attention when treating patients taking dabigatran, rivaroxaban and apixaban.